<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">08153</article-id><article-id pub-id-type="doi">10.7554/eLife.08153</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group></article-categories><title-group><article-title>Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-32763"><name><surname>Acosta-Alvear</surname><given-names>Diego</given-names></name><aff><institution content-type="dept">Department of Biochemistry and Biophysics</institution>, <institution>University of California, San Francisco</institution>, <addr-line><named-content content-type="city">San Francisco</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-32764"><name><surname>Cho</surname><given-names>Min Y</given-names></name><aff><institution content-type="dept">Department of Biochemistry and Biophysics</institution>, <institution>University of California, San Francisco</institution>, <addr-line><named-content content-type="city">San Francisco</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-32765"><name><surname>Wild</surname><given-names>Thomas</given-names></name><aff><institution content-type="dept">The Novo Nordisk Foundation Center for Protein Research</institution>, <institution>University of Copenhagen</institution>, <addr-line><named-content content-type="city">Copenhagen</named-content></addr-line>, <country>Denmark</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-32766"><name><surname>Buchholz</surname><given-names>Tonia J</given-names></name><aff><institution>Onyx Pharmaceuticals, Inc. an Amgen subsidiary</institution>, <addr-line><named-content content-type="city">South San Francisco</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-32767"><name><surname>Lerner</surname><given-names>Alana G</given-names></name><aff><institution>Onyx Pharmaceuticals, Inc. an Amgen subsidiary</institution>, <addr-line><named-content content-type="city">South San Francisco</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-32817"><name><surname>Simakova</surname><given-names>Olga</given-names></name><aff><institution content-type="dept">Department of Laboratory Medicine, Clinical Center</institution>, <institution>National Institutes of Health</institution>, <addr-line><named-content content-type="city">Bethesda</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-32769"><name><surname>Hahn</surname><given-names>Jamie</given-names></name><aff><institution content-type="dept">Department of Laboratory Medicine, Clinical Center</institution>, <institution>National Institutes of Health</institution>, <addr-line><named-content content-type="city">Bethesda</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-32770"><name><surname>Korde</surname><given-names>Neha</given-names></name><aff><institution content-type="dept">Multiple Myeloma Section, Lymphoid Malignancies Branch</institution>, <institution>National Cancer Institute</institution>, <addr-line><named-content content-type="city">Bethesda</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-32771"><name><surname>Landgren</surname><given-names>Ola</given-names></name><aff><institution content-type="dept">Multiple Myeloma Section, Lymphoid Malignancies Branch</institution>, <institution>National Cancer Institute</institution>, <addr-line><named-content content-type="city">Bethesda</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-32772"><name><surname>Maric</surname><given-names>Irina</given-names></name><aff><institution content-type="dept">Department of Laboratory Medicine, Clinical Center</institution>, <institution>National Institutes of Health</institution>, <addr-line><named-content content-type="city">Bethesda</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-2346"><name><surname>Choudhary</surname><given-names>Chunaram</given-names></name><aff><institution content-type="dept">The Novo Nordisk Foundation Center for Protein Research</institution>, <institution>University of Copenhagen</institution>, <addr-line><named-content content-type="city">Copenhagen</named-content></addr-line>, <country>Denmark</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-30198"><name><surname>Walter</surname><given-names>Peter</given-names></name><aff><institution content-type="dept">Department of Biochemistry and Biophysics</institution>, <institution>University of California, San Francisco</institution>, <addr-line><named-content content-type="city">San Francisco</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-30197"><name><surname>Weissman</surname><given-names>Jonathan S</given-names></name><aff><institution content-type="dept">Department of Cellular and Molecular Pharmacology</institution>, <institution>University of California, San Francisco</institution>, <addr-line><named-content content-type="city">San Francisco</named-content></addr-line>, <country>United States</country><email>Jonathan.Weissman@ucsf.edu</email></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-31951"><name><surname>Kampmann</surname><given-names>Martin</given-names></name><aff><institution content-type="dept">Department of Cellular and Molecular Pharmacology</institution>, <institution>University of California, San Francisco</institution>, <addr-line><named-content content-type="city">San Francisco</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-1075"><name><surname>Deshaies</surname><given-names>Raymond J</given-names></name><role>Reviewing editor</role><aff><institution>Howard Hughes Medical Institute, California Institute of Technology</institution>, <country>United States</country></aff></contrib></contrib-group><pub-date date-type="pub" publication-format="electronic"><day>01</day><month>09</month><year>2015</year></pub-date><volume>4</volume><elocation-id>e08153</elocation-id><supplementary-material><ext-link xlink:href="elife-08153-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material><history><date date-type="received"><day>16</day><month>04</month><year>2015</year></date><date date-type="accepted"><day>31</day><month>08</month><year>2015</year></date></history><permissions><license xlink:href="http://creativecommons.org/publicdomain/zero/1.0/"><license-p>This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">Creative Commons CC0</ext-link> public domain dedication.</license-p></license></permissions><abstract><p>Hallmarks of cancer, including rapid growth and aneuploidy, can result in non-oncogene addiction to the proteostasis network that can be exploited clinically. The defining example is the exquisite sensitivity of multiple myeloma (MM) to 20S proteasome inhibitors, such as carfilzomib. However, MM patients invariably acquire resistance to these drugs. Using a next-generation shRNA platform, we found that proteostasis factors, including chaperones and stress-response regulators, controlled the response to carfilzomib. Paradoxically, 19S proteasome regulator knockdown induced resistance to carfilzomib in MM and non-MM cells. 19S subunit knockdown did not affect the activity of the 20S subunits targeted by carfilzomib nor their inhibition by the drug, suggesting an alternative mechanism, such as the selective accumulation of protective factors. In MM patients, lower 19S levels predicted a diminished response to carfilzomib-based therapies. Together, our findings suggest that an understanding of network rewiring can inform development of new combination therapies to overcome drug resistance.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group></article-meta></front><back><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Tonia J Buchholz, is an employee of Onyx Pharmaceuticals, an Amgen subsidiary.</p></fn><fn fn-type="conflict" id="conf3"><p>Alana G Lerner, is an employee of Onyx Pharmaceuticals, an Amgen subsidiary.</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: The registered clinical research trial (NCT01402284) was approved by the National Cancer Institute (NCI) Institutional Review Board (IRB) and complied with the Declaration of Helsinki, the International Conference on Harmonization, and the Guidelines for Good Clinical Practice. All enrolled patients meeting criteria were consented with an IRB-approved document</p></fn></fn-group></back></article>